Last reviewed · How we verify

NCT04380844

Effects of an Activity Control System in Patients With Diabetes: a Randomized Controlled Trial

Status unknown NA Last updated 24 December 2020
What this trial tests

NA trial testing Beprevent in Diabetes Mellitus, Type 2 in 20 participants. Status unknown.

Timeline
1 February 2021
Primary endpoint
1 May 2021
1 November 2021

Quick facts

Lead sponsorMaimónides Biomedical Research Institute of Córdoba
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposehealth services research
Enrollment20
Start date1 February 2021
Primary completion1 May 2021
Estimated completion1 November 2021

Drugs / interventions tested

Conditions studied

Sponsor

Maimónides Biomedical Research Institute of Córdoba

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Using a smart device (Beprevent) to monitor activities of daily living improves the lifestyle of patients with DM2

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other Maimónides Biomedical Research Institute of Córdoba trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04380844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing